ALISO VIEJO, Calif., July 25, 2017 -- NVISION Eye Centers, a national leader in providing the finest suite of ophthalmology services for patients, is pleased to welcome Scott Asher to its leadership team as Vice President of Corporate Development.
“I’m excited to welcome Scott to the NVISION family and leadership team," said Tom Tooma, founder of NVISION. “His proven track record of driving strategic corporate initiatives will be key as we continue to expand our organization.”
Prior to joining NVISION’s leadership team, Scott served as Vice President of Corporate Development at Vantage Oncology/McKesson, where he was responsible for the development of relationships and strategic transactions with physicians, healthcare systems, payers and other strategic partners in the oncology sector.
He also served as Director of Corporate Development at DaVita Inc., one of the nation’s largest providers of dialysis and related services. His responsibilities included leading valuation, structuring, diligence, negotiation and execution of acquisitions, divestitures and joint ventures.
“NVISION Eye Centers is recognized as an exceptional leader in ophthalmology, and I’m excited to join such an innovative and dedicated team,” says Scott Asher. “With my background in finance and business strategy, paired with my experience in the healthcare industry, I look forward to building and expanding our network of partners to help even more patients see clearly.”
Before joining DaVita, Scott worked at Clear Capital Advisors focusing on middle market M&A advisory and capital raising, at Bear Stearns in both New York and Los Angeles in the Leveraged Finance/Financial Sponsors Group, and also as part of the M&A team. Scott began his professional career at Prudential Capital Group, a middle-market private placement lender participating in and originating senior debt, subordinated debt and mezzanine financings.
Scott is a graduate of The State University of New York at Geneseo and earned his MBA from the University of Rochester, NY.
ABOUT NVISION EYE CENTERS: NVISION Eye Centers is the premier provider of LASIK and cataract surgery in the U.S., with centers in California, Arizona, Nevada, Oregon, and Toronto, Canada. An innovative leader in ophthalmology, NVISION is dedicated to providing the best patient experience through the use of the latest technology and treatment by the most talented and experienced surgeons in the industry. NVISION was founded in 2010 by Tom Tooma, M.D., one of the earliest pioneers of LASIK who has performed more than 120,000 procedures throughout his esteemed career. With more than 2,000 eye doctors referring their patients and trusting their own eyes to NVISION surgeons, NVISION Eye Centers is the Eye Doctors' #1 Choice®.
For more information, visit www.NVISIONCenters.com or call (877) 455-9942.


Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Italy Fines Apple €98.6 Million Over App Store Dominance
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 



